Fluidic Sciences Secures £3m to Advance Microfluidic Protein Analysis Platforms

Fluidic Sciences Limited, a Royston based developer of microfluidic instruments, has raised an estimated £3m in new funding. The allotment, filed today, brings the company to an estimated post-money valuation of £12.1m.

Incorporated in April 2018, Fluidic Sciences develops and manufactures platforms designed for in-solution protein interaction analysis and high-throughput single-cell screening. The company operates as the home of the Sphere Bio and Fluidity One-M brands, delivering an end-to-end portfolio for complex biology.

The firm solves a critical bottleneck in the biomedical and biopharmaceutical industries. Traditionally, measuring protein interactions often requires immobilising proteins on a surface, which can alter their natural behaviour. Fluidic Sciences bypasses this issue with its proprietary microfluidic technology. By allowing researchers to analyse proteins in solution, the company provides highly accurate data on binding affinity, size, and concentration. These insights are vital for accelerating drug discovery, antibody development, and cell line engineering.

According to its latest corporate accounts, Fluidic Sciences operates with a core team of 8 employees, though its LinkedIn presence indicates a wider workforce of 27 staff members. The company has steadily built its commercial footprint, targeting researchers who require multiplex single-cell screening and robust biophysics data to make confident clinical decisions.

The latest funding round, allotted on 25 March 2026 and filed on 27 March 2026, injects £3m into the business. Specific investors were not disclosed in the latest filings. The £12.1m post-money valuation reflects the underlying value of its proprietary hardware and its established customer base within the global life sciences sector.

This capital injection arrives during a transitional period for the UK biotechnology and life sciences funding landscape. According to the latest data from the BioIndustry Association, UK biotech venture capital investment experienced a 13.2 percent year-on-year decline in 2025, falling to £1.79bn across 58 deals. The market was characterised by extreme investor caution and a heavy concentration of capital into a handful of massive funding rounds, leaving mid-sized scale-up financing constrained.

However, the sector is entering 2026 with renewed momentum. The final quarter of 2025 saw 22 completed deals, the highest quarterly count of the year, signalling a revitalised appetite among investors. Furthermore, the UK has firmly retained its status as Europe's leading national biotech market, capturing 30 percent of all European venture financing.

While headline grabbing mega-rounds in artificial intelligence and obesity drugs have dominated recent industry news, the successful £3m raise by Fluidic Sciences highlights a continued commitment to the essential hardware and instrumentation that makes advanced therapeutics possible. With fresh capital secured, the Royston based company is well positioned to expand the reach of its Fluidity One-M and Cyto-Mine Chroma platforms across the global biopharmaceutical market.